Trial Profile
Phase I Study: to Determine the Biological Activity of Two HPV16 E6 Specific Peptides Coupled to Amplivant®, a Toll-like Receptor Ligand in Patients Treated for HPV16-positive Tumors or Premalignant Lesions
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs ISA 201 (Primary)
- Indications Human papillomavirus infections; Oropharyngeal cancer; Precancerous conditions; Tumours
- Focus First in man; Pharmacodynamics
- 08 Nov 2022 According to an ISA Pharmaceuticals media release, this study published by Leiden University Medical Center (LUMC).
- 08 Nov 2022 According to an ISA Pharmaceuticals media release, data published in the Journal for ImmunoTherapy of Cancer.
- 08 Jun 2021 Results assessing safety and immunogenicity of AV-conjugated human papillomavirus (HPV)16-SLPs, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.